CureSearch Research Programs: Information for Applicants

In order to ensure that CureSearch funds the best science with the greatest potential to reach pediatric cancer patients in an accelerated time-frame, CureSearch employs a rigorous review process that engages members throughout the drug development ecosystem. Input of scientists, oncologists, and industry experts enables CureSearch to support projects that are positioned to succeed.

CureSearch application submissions and reviews follow a two-stage process. Applicants first must submit a “Letter of Intent” (LOI). LOIs are administratively reviewed by CureSearch Scientific Staff and then reviewed by the CureSearch Scientific Review Committee (SRC). Top scoring LOIs are invited to submit full proposals, which elaborate on the projects initially outlined in the LOI.

Funding Opportunity Announcement

The application window to submit Letters of Intent (LOIs) will open May 1, 2023. CureSearch will fund high potential projects that address areas of unmet need in pediatric cancer, leading to the development of better, less-toxic children’s cancer treatments.

Request for Applications Opens May 1, 2023
Letter of Intent Deadline May 26, 2023
LOI Notification/Full Applications Invited July 7, 2023
Full Applications Due September 29, 2023
Earliest Award Notification* January 2024
*Awards will be made on a rolling basis, pending the availability of funds.


Program Opportunity Summary Submission Site
Young Investigator

Read the 2023 YI RFA

An opportunity for funding up to $75,000 per year for up to three years. Provides seed support for bright researchers, early in their careers, pursuing exciting and novel research in pediatric oncology. LOI application window opens May 1, 2023 on ProposalCentral
Acceleration Initiative

Read the 2023 AI RFA

An opportunity for funding in the range of $500,000 to $1.5 million over three years. CureSearch’s Acceleration Initiative Acceleration Initiative projects are highly innovative, address a significant challenge in pediatric cancer drug development, and have a strong probability of clinical application — ready to reach patients within three to five years. LOI application window opens May 1, 2023 on ProposalCentral
Click here to add yourself to our mailing list and be the first to know about new RFAs.

Please email Holly Zink, Senior Director of Research and Programs, with any questions or comments.

Pin It on Pinterest

Scroll to Top